Ajanta Pharma is currently trading at Rs 1710.75, up by 9.90 points or 0.58% from its previous closing of Rs 1700.85 on the BSE.
The scrip opened at Rs 1703.00 and has touched a high and low of Rs 1715.00 and Rs 1690.00 respectively. So far 24018 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1745.00 on 26-Jul-2016 and a 52 week low of Rs. 1103.00 on 18-Jan-2016.
Last one week high and low of the scrip stood at Rs 1745.00 and Rs 1601.70 respectively. The current market cap of the company is Rs 15016.73 crore.
The promoters holding in the company stood at 73.78%, while Institutions and Non-Institutions held 12.06% and 14.16% respectively.
Ajanta Pharma has reported 22.01% rise in its net profit at Rs 99.91 crore for the quarter ended June 30, 2016 as compared to Rs 81.89 crore for the same quarter in the previous year. The company’s total income increased by 18.57% to Rs 421.47 crore for the quarter under review from Rs 355.45 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 39% rise in its net profit after taxes, minority interest and share of profit of associates at Rs 119.55 crore for the quarter ended June 30, 2016 as compared to Rs 86.01 crore for the same quarter in the previous year . Total Income of the company increased by 19.33% to Rs 476.48 crore for the quarter under review from Rs 399.31 crore for the same quarter ended June 30, 2015
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: